Building Capacity for Research on Cancer, Older Adults, and Under-Represented Populations: Methods and Lessons Learned From the Development of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center-Medicare Database

JCO Clin Cancer Inform. 2026 Mar;10:e2500276. doi: 10.1200/CCI-25-00276. Epub 2026 Mar 18.ABSTRACTPURPOSE: This study assessed the feasibility of developing the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC)-Medicare-linked database infrastructure by integ

T Tsung-Ying Lee

Ageing and pituitary neuroendocrine tumours (PitNETs): from bench to bedside

Endocr Relat Cancer. 2026 Mar 17:ERC-25-0535. doi: 10.1530/ERC-25-0535. Online ahead of print.ABSTRACTThe prevalence of pituitary neuroendocrine tumours (PitNETs) in elderly people (>65 years-old) is raising with life expectancy. Despite an increasing incidental detection on neuroimaging for unrelat

D Dario De Alcubierre

Mode of action-specific and cause-specific retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in anti-SS-A antibody-positive rheumatoid arthritis: The ANSWER cohort study

PLoS One. 2026 Mar 18;21(3):e0344747. doi: 10.1371/journal.pone.0344747. eCollection 2026.ABSTRACTAnti-SS-A (Ro) antibody-positive rheumatoid arthritis (RA) constitutes a clinically important subgroup, but its impact on retention of biologic or targeted synthetic disease-modifying antirheumatic drug

K Kazuma Nishisaka

Brand Manufacturer Coupons and Pharmaceutical Product Hopping

JAMA Netw Open. 2026 Mar 2;9(3):e262201. doi: 10.1001/jamanetworkopen.2026.2201.ABSTRACTIMPORTANCE: Biologic manufacturer copay coupon programs reduce patient out-of-pocket spending but may undermine biosimilar competition. Whether biologic manufacturers deploy coupons strategically to facilitate sh

J Jason B Gibbons